An­tho­ny Quinn ce­ments Ae­glea CEO spot; Hu­man Longevi­ty bumps David Karow up to the top

→ Af­ter prov­ing him­self in one year as in­ter­im CEO at Ae­glea Bio­Ther­a­peu­tics $AGLE, An­tho­ny Quinn is of­fi­cial­ly tak­ing on the post per­ma­nent­ly. Since he joined the Austin-based com­pa­ny as a board mem­ber in 2016, he’s seen it through an IPO and ini­ti­a­tion of sev­er­al Phase I tri­als for its rare dis­ease drug, AEB1102. A for­mer pro­fes­sor at Barts and the Lon­don School of Med­i­cine, Quinn pre­vi­ous­ly worked as CMO at Synage­va Bio­phar­ma un­til Alex­ion came along to snap it up. He will be helped at the helm by Bri­an Lawlis, Itero founder and ex-CEO, who’s just been ap­point­ed to the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER